Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
EXTON, Pa., April 10, 2019 /PRNewswire/ -- Self-reported oral disease-modifying therapy (DMT) class share has increased significantly over the past year...